Growth strategy for nutraceutical ingredient manufacturers
Your ingredients sell twice: to brands that buy science and a story, and to the CDMOs that buy specification, supply and price. Decide which health spaces, formats and customers each ingredient should win, business unit by business unit.
Built for how ingredient companies sell
- Portfolios run by business unitProbiotics and postbiotics, botanical extracts and teas, minerals and chelates, flavonoids, encapsulation. One cascade per ingredient, one consolidated portfolio view.
- Evidence that does not transferStrain-, extract- and form-specific studies mapped to each health space, with the clinical dose checked against a realistic daily serving in every format.
- Price per kg against the comparablesPremium versus generic and branded alternatives, margin per kg and cost per daily dose, before the pitch.
- Two buyers, two casesBrand marketing gets the consumer story. CDMO formulation and procurement get specification, supply and price.
- Regulatory route by countryEU claims and novel food, US NDI and GRAS, Japan Foods with Function Claims, Brazil ANVISA, China SAMR, screened per Play market.
- Supply and traceabilityCrop and harvest risk, fermentation and extraction capacity, and the sustainability data large brands now ask their suppliers for.
Questions it answers
Which platform next?
After menopause and sleep, where should your portfolio build, and with which ingredients already in hand?
Which customers first?
Which brands and which CDMOs to prioritize this quarter, and the proof each one needs.
Which gaps to close?
The health spaces your ingredients do not cover yet: build the evidence, partner or buy.
What you get
- A Where 2 Play / How 2 Win for your business, with time-limited access to ZUGPATH to build and compare scenarios.
- A cascade for each ingredient and each key customer, with a consolidated portfolio plan, ingredient stacks and a 90-day roadmap.
- A SWOT against named competitors, same-molecule suppliers and substitute ingredients, with the whitespace tested against your capabilities.
- The market read from ZUGPATH Intelligentsia, every figure sourced, plus the data you already license.
Add Platform creation
A separate module, priced on its own, for when the strategic choice is made.
Product concepts and platform building
Co-creation sessions with your customers on the chosen territory: 3–5 concepts per session, each tied to one of your ingredients, with the science translated into storytelling and claims screened for the EU and the US.
How a pilot runs
Define your objectives
Bring your challenge and the goals behind it.
Book a session
We work through your Where 2 Play / How 2 Win together on ZUGPATH.
Refine it on your own
Run and compare scenarios with your team.
Download your report
Your Where 2 Play / How 2 Win report, ready to share.
Refresh every quarter
Revisit, compare and update the plan as the market moves.
Start with a pilot
Define your objectives and bring your challenge. Book a session, refine it on your own, download your Where 2 Play / How 2 Win report and refresh it every quarter.
plimena@imageneerconsulting.com
Questions from ingredient manufacturers
How does ZUGPATH read right to win for an ingredient manufacturer?
Against your ingredient portfolio. Each health space is matched to the ingredients you hold, the evidence behind each one and the dose that evidence needs, so the gaps show before you invest.
We run several ingredient businesses. Can it handle a portfolio?
Yes. Each ingredient gets its own cascade. The consolidated plan shows where they stack into one solution, where they overlap, and where two business units are about to pitch the same brand.
Can we run it per customer?
Yes, for brands and for the CDMOs that formulate for them. The brand gets the science and the consumer story; the CDMO gets specification, dose per serving, supply and price.
Does it handle probiotics and botanicals properly?
Evidence is read strain by strain and extract by extract, because a study on one does not transfer to another. Probiotic doses in CFU, botanical standardization and the EU limits on the word probiotic are all part of the screen.
Where does the market data come from?
ZUGPATH Intelligentsia, the gated Nutraceuticals Index, feeds every analysis. Premium clients also get the licensed NBJ layer. Every figure carries its source.
Do we get product concepts?
Through Platform creation, a separate module priced on its own. Each session delivers 3–5 concepts tied to your ingredients, with claims screened for the EU and the US.